Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05963282 · ClinicalTrials.gov registry record
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 9,870
- Enrollment target
NCT05963282: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05963282 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9,870 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05963282 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 9,870 participants
- Enrollment target
Study Summary
This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blocker (ARB) therapy for HF in the United States (US) using the secondary source of data, Optum Electronic Health Records (EHR).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,870 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2022-07-19 |
What the finished NCT05963282 record still lists
NCT05963282 is an observational study that tracks outcomes without assigning an intervention. Its 9,870 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05963282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05963282 about?
NCT05963282 is a clinical study titled "Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients". This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (ACEi)/angiotensin re...
What is the current status of trial NCT05963282?
This trial is currently completed. The enrollment target is 9,870 participants. The study started on 2021-11-29. Estimated completion is 2022-07-19.
Who is sponsoring clinical trial NCT05963282?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI